Rituximab induction for liver transplantation to prevent recurrence of primary sclerosing cholangitis

Rituximab induction for liver transplantation to prevent recurrence of primary sclerosing cholangitis - Rituximab induction for liver transplantation to prevent recurrence of primary sclerosing cholangitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022897

Enrollment

Registered

2016-07-15

Start date

2016-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary sclerosing cholangitis

Interventions

RItuximab induction for liver transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients have to meet the diagnostic criteria of PSC, Age range 2>, <65 indicated for liver transplantation, having a living donor with autonomy

Exclusion criteria

Exclusion criteria: Re-trenaplantation Deceased donor transplantation, Domino Transplantation

Design outcomes

Primary

Measure	Time frame
The rate of recurrence of PSC after liver transplantation, and recurrence free liver graft survival	—

Countries

Japan

Contacts

Public ContactYohei Yamada

Keio University Hospital Department of Pediatric Surgery

yohei@z7.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026